Neuronetics Ptb Ratio vs Price To Sales Ratio Analysis

STIM Stock

USD 0.89 0.05 5.95%

Neuronetics financial indicator trend analysis is infinitely more than just investigating Neuronetics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Neuronetics is a good investment. Please check the relationship between Neuronetics Ptb Ratio and its Price To Sales Ratio accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Neuronetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.

Ptb Ratio vs Price To Sales Ratio

Ptb Ratio vs Price To Sales Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Neuronetics Ptb Ratio account and Price To Sales Ratio. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Neuronetics' Ptb Ratio and Price To Sales Ratio is 0.9. Overlapping area represents the amount of variation of Ptb Ratio that can explain the historical movement of Price To Sales Ratio in the same time period over historical financial statements of Neuronetics, assuming nothing else is changed. The correlation between historical values of Neuronetics' Ptb Ratio and Price To Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ptb Ratio of Neuronetics are associated (or correlated) with its Price To Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price To Sales Ratio has no effect on the direction of Ptb Ratio i.e., Neuronetics' Ptb Ratio and Price To Sales Ratio go up and down completely randomly.

Correlation Coefficient

0.9

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Ptb Ratio

Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Neuronetics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Neuronetics sales, a figure that is much harder to manipulate than other Neuronetics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Most indicators from Neuronetics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Neuronetics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Neuronetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.As of the 22nd of November 2024, Selling General Administrative is likely to drop to about 19.4 M. Issuance Of Capital Stock is expected to grow at the current pace this year

	2023	2024 (projected)
Depreciation And Amortization	2.0M	1.4M
Interest Income	4.2M	3.3M

Depreciation And Amortization Interest Income

Neuronetics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Inventory	Other Current Assets
Total Assets		0.61	0.67	0.59	0.97	0.61	0.97	0.81	0.86	-0.73	-0.82	0.88	0.96	0.85	0.83	0.5	0.7	0.96	0.74	0.94	0.92	0.61	-0.94	0.96	0.8	0.79
Short Long Term Debt Total	0.61		0.62	0.33	0.52	0.64	0.55	0.55	0.58	-0.13	-0.71	0.71	0.49	0.63	0.51	0.14	0.85	0.49	0.72	0.65	0.65	0.74	-0.45	0.63	0.68	0.72
Other Current Liab	0.67	0.62		0.88	0.63	0.28	0.65	0.7	0.43	-0.27	-0.77	0.5	0.55	0.62	0.52	-0.05	0.49	0.55	0.86	0.73	0.75	0.34	-0.62	0.71	0.84	0.68
Total Current Liabilities	0.59	0.33	0.88		0.61	0.22	0.61	0.76	0.42	-0.32	-0.64	0.43	0.5	0.58	0.52	0.0	0.18	0.5	0.66	0.64	0.7	0.11	-0.65	0.64	0.68	0.52
Total Stockholder Equity	0.97	0.52	0.63	0.61		0.6	1.0	0.82	0.85	-0.72	-0.81	0.88	0.95	0.81	0.78	0.41	0.65	0.95	0.7	0.94	0.91	0.63	-0.99	0.96	0.73	0.77
Other Liab	0.61	0.64	0.28	0.22	0.6		0.58	0.37	0.86	-0.61	-0.35	0.73	0.69	0.34	0.35	0.21	0.46	0.69	0.21	0.47	0.44	0.8	-0.57	0.51	0.24	0.33
Net Tangible Assets	0.97	0.55	0.65	0.61	1.0	0.58		0.83	0.83	-0.67	-0.85	0.9	0.93	0.83	0.78	0.38	0.69	0.94	0.73	0.96	0.92	0.64	-0.98	0.96	0.75	0.82
Property Plant And Equipment Net	0.81	0.55	0.7	0.76	0.82	0.37	0.83		0.64	-0.37	-0.85	0.75	0.65	0.94	0.88	0.44	0.57	0.67	0.79	0.87	0.96	0.38	-0.83	0.88	0.85	0.79
Current Deferred Revenue	0.86	0.58	0.43	0.42	0.85	0.86	0.83	0.64		-0.76	-0.62	0.82	0.91	0.64	0.7	0.52	0.5	0.91	0.39	0.75	0.7	0.72	-0.81	0.74	0.51	0.58
Net Debt	-0.73	-0.13	-0.27	-0.32	-0.72	-0.61	-0.67	-0.37	-0.76		0.23	-0.57	-0.86	-0.38	-0.47	-0.48	-0.2	-0.86	-0.17	-0.47	-0.47	-0.37	0.71	-0.61	-0.29	-0.17
Retained Earnings	-0.82	-0.71	-0.77	-0.64	-0.81	-0.35	-0.85	-0.85	-0.62	0.23		-0.74	-0.67	-0.87	-0.78	-0.26	-0.76	-0.68	-0.88	-0.96	-0.91	-0.57	0.77	-0.85	-0.89	-0.98
Accounts Payable	0.88	0.71	0.5	0.43	0.88	0.73	0.9	0.75	0.82	-0.57	-0.74		0.85	0.77	0.67	0.37	0.8	0.85	0.65	0.86	0.83	0.69	-0.85	0.87	0.6	0.77
Cash	0.96	0.49	0.55	0.5	0.95	0.69	0.93	0.65	0.91	-0.86	-0.67	0.85		0.68	0.7	0.46	0.57	1.0	0.55	0.84	0.78	0.61	-0.91	0.86	0.61	0.64
Non Current Assets Total	0.85	0.63	0.62	0.58	0.81	0.34	0.83	0.94	0.64	-0.38	-0.87	0.77	0.68		0.96	0.61	0.72	0.69	0.82	0.89	0.96	0.43	-0.78	0.9	0.9	0.84
Non Currrent Assets Other	0.83	0.51	0.52	0.52	0.78	0.35	0.78	0.88	0.7	-0.47	-0.78	0.67	0.7	0.96		0.77	0.58	0.71	0.66	0.82	0.89	0.39	-0.74	0.83	0.85	0.74
Other Assets	0.5	0.14	-0.05	0.0	0.41	0.21	0.38	0.44	0.52	-0.48	-0.26	0.37	0.46	0.61	0.77		0.24	0.47	0.11	0.36	0.43	0.08	-0.34	0.41	0.38	0.27
Long Term Debt	0.7	0.85	0.49	0.18	0.65	0.46	0.69	0.57	0.5	-0.2	-0.76	0.8	0.57	0.72	0.58	0.24		0.57	0.8	0.76	0.74	0.71	-0.58	0.76	0.7	0.82
Cash And Short Term Investments	0.96	0.49	0.55	0.5	0.95	0.69	0.94	0.67	0.91	-0.86	-0.68	0.85	1.0	0.69	0.71	0.47	0.57		0.55	0.84	0.78	0.62	-0.91	0.87	0.62	0.64
Net Receivables	0.74	0.72	0.86	0.66	0.7	0.21	0.73	0.79	0.39	-0.17	-0.88	0.65	0.55	0.82	0.66	0.11	0.8	0.55		0.84	0.88	0.45	-0.68	0.85	0.93	0.85
Common Stock Total Equity	0.94	0.65	0.73	0.64	0.94	0.47	0.96	0.87	0.75	-0.47	-0.96	0.86	0.84	0.89	0.82	0.36	0.76	0.84	0.84		0.95	0.61	-0.91	0.94	0.86	0.94
Common Stock Shares Outstanding	0.92	0.65	0.75	0.7	0.91	0.44	0.92	0.96	0.7	-0.47	-0.91	0.83	0.78	0.96	0.89	0.43	0.74	0.78	0.88	0.95		0.54	-0.9	0.97	0.91	0.86
Long Term Debt Total	0.61	0.74	0.34	0.11	0.63	0.8	0.64	0.38	0.72	-0.37	-0.57	0.69	0.61	0.43	0.39	0.08	0.71	0.62	0.45	0.61	0.54		-0.6	0.6	0.43	0.56
Non Current Liabilities Total	-0.94	-0.45	-0.62	-0.65	-0.99	-0.57	-0.98	-0.83	-0.81	0.71	0.77	-0.85	-0.91	-0.78	-0.74	-0.34	-0.58	-0.91	-0.68	-0.91	-0.9	-0.6		-0.94	-0.69	-0.71
Capital Surpluse	0.96	0.63	0.71	0.64	0.96	0.51	0.96	0.88	0.74	-0.61	-0.85	0.87	0.86	0.9	0.83	0.41	0.76	0.87	0.85	0.94	0.97	0.6	-0.94		0.86	0.81
Inventory	0.8	0.68	0.84	0.68	0.73	0.24	0.75	0.85	0.51	-0.29	-0.89	0.6	0.61	0.9	0.85	0.38	0.7	0.62	0.93	0.86	0.91	0.43	-0.69	0.86		0.83
Other Current Assets	0.79	0.72	0.68	0.52	0.77	0.33	0.82	0.79	0.58	-0.17	-0.98	0.77	0.64	0.84	0.74	0.27	0.82	0.64	0.85	0.94	0.86	0.56	-0.71	0.81	0.83

Click cells to compare fundamentals

Neuronetics Account Relationship Matchups

Neuronetics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	100.2M	78.7M	141.2M	116.9M	115.8M	100.9M
Short Long Term Debt Total	34.3M	38.3M	39.5M	39.7M	62.5M	44.7M
Other Current Liab	9.0M	6.0M	6.9M	13.4M	10.9M	9.3M
Total Current Liabilities	27.7M	13.7M	15.7M	33.2M	19.8M	20.5M
Total Stockholder Equity	47.9M	25.5M	85.2M	57.1M	34.2M	35.9M
Other Liab	2.1M	1.7M	1.5M	829K	746.1K	1.2M
Net Tangible Assets	46.7M	25.5M	85.2M	57.1M	65.6M	68.9M
Property Plant And Equipment Net	4.9M	4.1M	5.1M	5.3M	4.8M	3.9M
Current Deferred Revenue	2.2M	2.0M	2.5M	2.0M	1.6M	2.2M
Net Debt	(41.4M)	(10.6M)	(54.6M)	(30.6M)	2.8M	2.9M
Retained Earnings	(250.1M)	(277.5M)	(308.7M)	(345.9M)	(376.1M)	(394.9M)
Accounts Payable	4.6M	3.7M	4.3M	2.4M	4.8M	3.8M
Cash	75.7M	49.0M	94.1M	70.3M	59.7M	68.7M
Non Current Assets Total	11.7M	13.6M	25.9M	18.1M	22.0M	13.4M
Non Currrent Assets Other	5.1M	7.2M	19.1M	11.6M	8.6M	7.4M
Other Assets	5.6M	12.9M	167.1M	9.2M	1.0	0.95
Long Term Debt	19.9M	34.6M	35.3M	22.8M	59.3M	34.0M
Cash And Short Term Investments	76.6M	50.8M	96.3M	71.9M	60.6M	69.7M
Net Receivables	6.6M	7.2M	7.8M	13.8M	17.8M	9.2M
Common Stock Total Equity	177K	186K	191K	273K	314.0K	329.6K
Common Stock Shares Outstanding	18.4M	18.8M	25.5M	26.9M	28.7M	17.5M
Long Term Debt Total	30.4M	19.9M	34.6M	22.8M	26.3M	28.2M
Liabilities And Stockholders Equity	100.2M	78.7M	141.2M	116.9M	115.8M	100.9M
Non Current Liabilities Total	24.6M	39.5M	40.3M	26.6M	61.8M	63.4M
Capital Surpluse	291.9M	297.8M	302.8M	402.7M	463.1M	238.9M
Inventory	2.8M	3.7M	6.6M	8.9M	8.1M	5.0M
Other Current Assets	2.5M	3.3M	4.6M	4.2M	7.3M	7.6M
Other Stockholder Equity	297.8M	302.8M	393.6M	402.7M	410.0M	274.4M
Total Liab	52.3M	53.2M	56.0M	59.8M	81.6M	78.2M
Property Plant And Equipment Gross	4.9M	4.1M	5.1M	5.3M	7.6M	4.3M
Total Current Assets	88.5M	65.0M	115.3M	98.8M	93.8M	87.4M
Common Stock	186K	191K	264K	273K	291K	190.6K
Property Plant Equipment	4.9M	730K	5.1M	2.0M	2.3M	2.7M
Net Invested Capital	79M	60.1M	120.5M	93.0M	93.5M	60.4M
Net Working Capital	60.8M	51.3M	99.6M	65.6M	74.0M	75.0M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Neuronetics is a strong investment it is important to analyze Neuronetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neuronetics' future performance. For an informed investment choice regarding Neuronetics Stock, refer to the following important reports:

How To Invest In Neuronetics

Details

Is Neuronetics Stock a good investment?

Details

What is Neuronetics' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Neuronetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.

You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuronetics. If investors know Neuronetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuronetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.22)

Revenue Per Share

2.453

Quarterly Revenue Growth

(0.07)

Return On Assets

(0.17)

Return On Equity

(1.00)

The market value of Neuronetics is measured differently than its book value, which is the value of Neuronetics that is recorded on the company's balance sheet. Investors also form their own opinion of Neuronetics' value that differs from its market value or its book value, called intrinsic value, which is Neuronetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuronetics' market value can be influenced by many factors that don't directly affect Neuronetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Neuronetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuronetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuronetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Neuronetics Ptb Ratio vs Price To Sales Ratio Analysis

Ptb Ratio vs Price To Sales Ratio

Ptb Ratio vs Price To Sales Ratio Correlation Analysis

Correlation Coefficient

Ptb Ratio

Price To Sales Ratio

Neuronetics fundamental ratios Correlations

Neuronetics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Neuronetics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Tangible Assets	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash
Total Stockholder Equity	+ 0.97	Total Assets
Net Tangible Assets	+ 0.97	Total Assets
Capital Surpluse	+ 0.97	Common Stock Shares Outstanding
Cash	+ 0.96	Total Assets

Non Current Liabilities Total	- 0.99	Total Stockholder Equity
Other Current Assets	- 0.98	Retained Earnings
Non Current Liabilities Total	- 0.98	Net Tangible Assets
Common Stock Total Equity	- 0.96	Retained Earnings
Capital Surpluse	- 0.94	Non Current Liabilities Total
Non Current Liabilities Total	- 0.94	Total Assets